Cantargia reaches recruitment milestone and focuses nadunolimab development on upcoming randomized studies
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced that the clinical trials CAPAFOUR and CESTAFOUR have enrolled enough patients to halt recruitment. Preliminary results show acceptable safety of the chemotherapy combinations with Cantargia’s lead asset, the IL1RAP-binding antibody nadunolimab (CAN04), as well as signs of efficacy in a cohort of non-small cell lung cancer (NSCLC) patients treated with nadunolimab and gemcitabine/cisplatin in CESTAFOUR. Consequently, clinical development of nadunolimab will focus on planned randomized trials in the lead indications. Additionally,